The Korean drugmaker says it will show two sets of findings on its oral semaglutide for obesity and diabetes at the AAPS annual meeting.
Recap by typeshit. Full story at Health Chosun.
Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
24:26
A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
Researchers found a 44% relative drop over five years, though an outside expert told Newsweek that equals about 3 to 5 points. They also flag a lithium toxicity risk early on.
15:57
A video on Chinese supply behind the peptide trend and the open question of what is actually in the vials people buy.
Loading…